This afternoon we watched Merck & rise 1.5% to a price of $78.11 per share. The Large-Cap Pharmaceutical company is now trading -23.36% below its average target price of $101.91. Analysts have set target prices ranging from $82.0 to $138.0 per share for Merck &, and have given the stock an average rating of buy.
The stock has a very low short interest at 1.7%, and a short ratio of 2.12. At 0.06%, the company's rate of insider ownership does not indicate that management is heavily invested in the corporation. Finally, we also note that a significant number of institutional investors are invested in the stock, with 80.9% of Merck &'s shares being owned by this investor type.
Institutions Invested in Merck &
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-03-31 | Vanguard Group Inc | 10% | 252,513,381 | $19,722,558,470 |
| 2025-03-31 | Blackrock Inc. | 9% | 225,398,231 | $17,604,729,588 |
| 2025-03-31 | State Street Corporation | 5% | 120,529,640 | $9,413,967,936 |
| 2025-03-31 | Wellington Management Group, LLP | 3% | 81,669,651 | $6,378,808,365 |
| 2025-03-31 | Geode Capital Management, LLC | 2% | 59,657,270 | $4,659,531,273 |
| 2025-03-31 | Charles Schwab Investment Management, Inc. | 2% | 49,229,283 | $3,845,053,313 |
| 2025-03-31 | Morgan Stanley | 2% | 43,114,452 | $3,367,454,418 |
| 2024-12-31 | NORGES BANK | 1% | 34,979,885 | $2,732,104,035 |
| 2025-03-31 | FMR, LLC | 1% | 31,808,043 | $2,484,367,305 |
| 2025-03-31 | Bank of America Corporation | 1% | 31,084,245 | $2,427,835,060 |
Besides an analyst consensus of strong upside potential, other market factors point to there being positive market sentiment on Merck &.
